2 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
Follow HER2: new trials by email Literature Review of HER2 trials Research Report on HER2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression RC48, Tislelizumab - Non-Muscle Invasive Bladder Cancer, HER2 | Phase 2 | Unknown | RenJi Hospital | 20 | 2023-08-05 | 2023-08-31 |
| Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System chemotherapy in combination with trastuzumab for arm1, chemotherapy in combination with trastuzumab for arm2, chemotherapy in combination with trastuzumab for arm3 - Targeted Therapy, HER2 | Phase 2 | Unknown | Shen Lin | 100 | 2017-07-01 | 2019-07-19 |
Biliary Tract Neoplasms (1) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Non-Muscle Invasive Bladder Neoplasms (1)
Carcinoma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Biliary Tract Diseases (1) · Carcinoma, Squamous Cell (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Esophageal Diseases (1) · Esophageal Neoplasms (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1)
26S proteasome non-ATPase regulatory subunit 13 (1) · Drug Therapy (1) · JPT1 protein, human (1) · Trastuzumab (1) · disitamab vedotin (1) · tislelizumab (1)
RenJi Hospital (1) · Shen Lin (1)
China (2)
Lin Shen, Master (1)